Your browser doesn't support javascript.
loading
Identification of a Druggable Pathway Controlling Glioblastoma Invasiveness.
Pencheva, Nora; de Gooijer, Mark C; Vis, Daniel J; Wessels, Lodewyk F A; Würdinger, Tom; van Tellingen, Olaf; Bernards, René.
Afiliación
  • Pencheva N; Division of Molecular Carcinogenesis and Cancer Genomics Center Netherlands, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.
  • de Gooijer MC; Division of Pharmacology, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.
  • Vis DJ; Division of Molecular Carcinogenesis and Cancer Genomics Center Netherlands, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.
  • Wessels LFA; Division of Molecular Carcinogenesis and Cancer Genomics Center Netherlands, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.
  • Würdinger T; Department of Neurosurgery, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
  • van Tellingen O; Division of Pharmacology, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands. Electronic address: o.v.tellingen@nki.nl.
  • Bernards R; Division of Molecular Carcinogenesis and Cancer Genomics Center Netherlands, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands. Electronic address: r.bernards@nki.nl.
Cell Rep ; 20(1): 48-60, 2017 07 05.
Article en En | MEDLINE | ID: mdl-28683323
Diffuse and uncontrollable brain invasion is a hallmark of glioblastoma (GBM), but its mechanism is understood poorly. We developed a 3D ex vivo organotypic model to study GBM invasion. We demonstrate that invading GBM cells upregulate a network of extracellular matrix (ECM) components, including multiple collagens, whose expression correlates strongly with grade and clinical outcome. We identify interferon regulatory factor 3 (IRF3) as a transcriptional repressor of ECM factors and show that IRF3 acts as a suppressor of GBM invasion. Therapeutic activation of IRF3 by inhibiting casein kinase 2 (CK2)-a negative regulator of IRF3-downregulated the expression of ECM factors and suppressed GBM invasion in ex vivo and in vivo models across a panel of patient-derived GBM cell lines representative of the main molecular GBM subtypes. Our data provide mechanistic insight into the invasive capacity of GBM tumors and identify a potential therapy to inhibit GBM invasion.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Glioblastoma / Quinasa de la Caseína II / Inhibidores Enzimáticos / Factor 3 Regulador del Interferón / Matriz Extracelular / Antineoplásicos Tipo de estudio: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Cell Rep Año: 2017 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Glioblastoma / Quinasa de la Caseína II / Inhibidores Enzimáticos / Factor 3 Regulador del Interferón / Matriz Extracelular / Antineoplásicos Tipo de estudio: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Cell Rep Año: 2017 Tipo del documento: Article